Lampalizumab clinical trials
Also written FCFD4514S and RO5490249.
How each study uses lampalizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses lampalizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic AtrophyCompletedPhase 1Genentech, Inc.NCT00973011Written as FCFD4514S
- A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedPhase 3Hoffmann-La RocheNCT02247531Written as Lampalizumab
- A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic AtrophyCompletedPhase 2Genentech, Inc.NCT02288559Written as Lampalizumab
- An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic AtrophyTerminatedPhase 2Genentech, Inc.NCT01602120Written as Lampalizumab
- A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedPhase 3Hoffmann-La RocheNCT02247479Written as Lampalizumab
- Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)TerminatedPhase 3Hoffmann-La RocheNCT02745119Written as Lampalizumab
- A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic AtrophyCompletedPhase 2Genentech, Inc.NCT01229215Written as FCFD4514S
Codes
What other systems call lampalizumab · ClinicalTrials.gg INT000368
- MeSH (NLM) C000603963lampalizumabOne source NLM
- UNII (FDA) UWU93Y99R3LAMPALIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6482369LampalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123730LampalizumabOne source FDA
- DrugBank DB11826One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603963 | lampalizumab | One source NLM |
| UNII (FDA) | UWU93Y99R3 | LAMPALIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6482369 | Lampalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123730 | Lampalizumab | One source FDA |
| DrugBank | DB11826 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.